Zhong Guo Jing Ying Bao·2025-12-23 08:29Core Viewpoint - Fosun Pharma has reported significant sales figures for its Alzheimer's treatment, Ganluo Sodium Capsules, but faces challenges in future commercialization due to regulatory hurdles and ongoing clinical trials [2][3]. Sales Data Summary - The cumulative sales amount for Ganluo Sodium Capsules since its approval in 2019 has reached 1.92 billion RMB, with total sales quantity at 6.7711 million boxes [2]. - Sales figures from 2019 to 2025 show a fluctuating trend, with a peak in 2020 at 458.84 million RMB and a notable drop in 2022 to 182.78 million RMB, followed by a recovery to 377.73 million RMB in 2023 [2]. Investment and Regulatory Challenges - Fosun Pharma plans to invest 1.412 billion RMB to gain controlling interest in Green Valley Pharmaceutical, the producer of Ganluo Sodium Capsules [3]. - Starting from November 2024, Ganluo Sodium Capsules will not be commercially produced, significantly impacting sales projections for 2025 [3]. - The company is currently engaged in post-marketing confirmatory clinical trials, with 580 out of 1950 planned patients enrolled as of December 15, 2025, indicating a long timeline for completion and regulatory approval [3].